Changes this week
Changes detected in the 7 days to Nov 21, 2026
- Notable: CPAP vs High-Flow Nasal Cannula for Treating Sleep Apnea in Children Recruitment opened
- Notable: Promoting Physical Activity Among Young · Autism Recruitment opened
- Notable: Juveena™ Hydrogel System Following Transcervical Gynecologic Procedures (TCGP) At High-Risk for Intrauterine Adhesions Results posted: Nov 19, 2026
- Notable: Follow-up Study of SAT-3247 · Duchenne Muscular Dystrophy Including Those Who Participated in SAT-3247-CL-101 Start date pushed from Aug 20, 2025 to Sep 25, 2025
- Notable: PRO1160 (GEN1160) in Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) (PRO1160-001) Results posted: Nov 19, 2026
- Notable: REGN5381 · Heart Failure With Reduced Ejection Fraction Results posted: Nov 19, 2026
- Notable: Ph2, Study to Assess the Safety and Efficacy of GPC 100 and Propranolol With and Without G-CSF for the Mobilization of Stem Cells · Multiple Myeloma Undergoing Autologous Stem Cell Transplant Results posted: Nov 19, 2026
- Notable: Oral ZL-65 Tablets in Healthy and Obese · Cardiovascular Risk Eligibility criteria changed
- Notable: ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration Start date pushed from Jul 13, 2018 to Jan 30, 2019
- Notable: Performance of the Next-Generation SAFESYNC Transcatheter Heart Valve · Severe Aortic Stenosis Enrollment increased: 40 → 210 participants
- Notable: Neuroplasticity Enhancement From Cognitive Training Reinforced by Psilocybin Eligibility criteria changed
- Notable: Anti-Cancer Drug, Brenetafusp (IMCF106C), in Rare Cancers Start date pushed from Nov 23, 2026 to Jan 19, 2027
- Notable: Baricitinib · Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis Eligibility criteria changed
- Notable: H1ssF-3928 mRNA-LNP in Healthy Adults Results posted: Nov 19, 2026
- Notable: FESS With or Without Intranasal Desmopressin in Chronic Rhinosinusitis With Nasal Polyps Start date pushed from Oct 15, 2026 to Jan 15, 2027
- Notable: Type O Whole Blood and Assessment of Age During Prehospital Resuscitation Trial Results posted: Nov 19, 2026
- Notable: EFFET - Study of Executive Functions Regarding the Usability and User Experience of Assistive Technologies Among the Elderly Start date pushed from Oct 1, 2026 to Jan 15, 2027
- Notable: High Risk Neuroblastoma Study 1 of SIOP-Europe (SIOPEN) Primary completion date changed from estimate of Sep 30, 2021 to Jan 30, 2025
- Notable: Telephone Delivered Weight Loss, Nutrition, Exercise WeLNES Study Results posted: Nov 19, 2026
- Notable: CEUS Evaluation of Hydrocephalus in Neonates and Infants Start date pushed from Nov 30, 2026 to Dec 30, 2026
- Notable: PEP-CMV Vaccine Targeting CMV Antigen · Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma Eligibility criteria changed
- Notable: MRI Study of OnabotulinumtoxinA (OnabotA) Effect on Jaw Muscle Pain Start date pushed from Oct 2026 to Dec 1, 2026
- Notable: Elderly/Frail Pts With Newly Diagnosed or Recurrent Malignant Glioma Treated With Cesium-131 GammaTile® Start date pushed from Oct 2026 to Dec 2026
- Notable: Rectus Sheath Block for Analgesia After Gynecological Laparotomy Results posted: Nov 19, 2026
- Notable: Concurrent XRD-0394 With Radiation Therapy for High Grade Gliomas Enrollment increased: 39 → 84 participants
- Stopped: terminated, suspended or withdrawn
- Notable: the plan changed
- Minor: routine updates